BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69d3cc7ba09ea
DTSTAMP:20260406T110843
DTSTART:20110311T113000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20110311T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/35606
LOCATION:Université de Montréal - Pavillon Claire-McNicoll\, 2900\, chemi
 n de la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Understanding and targeting the oncogene eIF4E in cancer
DESCRIPTION:Conférence du Dre Katherine L. Borden\, chercheure principale\
 , Institut de recherche en immunologie et en cancérologie et professeure 
 titulaire au Département de pathologie et biologie cellulaire de l'Unive
 rsité de Montréal. Cette conférence sera prononcée en anglais. Résum
 é My laboratory focuses on determining the molecular basis for the oncoge
 nic activity of the eukarytotic translation initiation factor eIF4E. eIF4E
  is upregulated in 30% of human cancers including a subset of acute myeloi
 d leukemia (AML) patients. In order for eIF4E to oncogenically transform c
 ells it modulates the mRNA translation and mRNA export of a specific subse
 t of mRNAs involved in proliferation and survival.Our studies focus on det
 ermining the molecular basis for eIF4E dependent mRNA export. We have dete
 rmined that eIF4E dependent mRNA export occurs through a pathway distinct 
 from bulk mRNA. Further\, we have determined that eIF4E can act both upstr
 eam and downstream of Akt signaling\, and this activity is in part mediate
 d by its mRNA export functions. We have used structural methods to underst
 and the regulation of eIF4E including how the promyelocytic leukemia prote
 in PML is able to potently inhibit the nuclear mRNA export activity of eIF
 4E and thereby suppress oncogenic transformation by eIF4E.Our studies sugg
 ested that targeting eIF4E could lead to clinical benefit. In this regard\
 , we identified the anti-viral drug ribavirin as a competitive inhibitor o
 f the natural ligand of eIF4E (m7G cap). In a phase II clinical trial\, ri
 bavirin monotherapy led to remissions and hematological responses in patie
 nts with poor prognosis AML. Conférence présentée par le Département d
 e microbiologie et immunologie de l'Université de Montréal. Crédit phot
 o : site Web du Département de microbiologie et immunologie
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR